鬼吹灯之牧野诡事

Pfizer cuts full-year outlook due to declining sales of Covid-19-related products_我的网站

A |     Shares of Pfizer are in retreat on the first day of trading after the drug company said sales of its COVID-19 vaccine and its coronavirus treatment are weaker than it had expected and cut revenue projections by $9 billion for the year. Falling sales of both clipped sales in the second quarter, but Pfizer said in August that it expected a rebound in the second half of 2023. Shares of Pfizer slipped more than 1% before the opening bell Monday and Moderna, which is heavily reliant on the competing vaccine it makes, slid nearly 5%. Pfizer said Friday that global usage of Paxlovid is trending slightly above last year, but that it's still below expectations.The fall vaccination period just began and the New York City drugmaker said that it's too soon to get a handle on vaccination rates for the year.Full-year revenue for Paxlovid and Comirnaty is expected to be approximately $12.5 billion, short $9 billion of what it had expected. Pfizer is lowering its full-year revenue expectations for Paxlovid by approximately $7 billion. That number also accounts for delayed commercialization of the product, which was pushed to January 2024 from the company's previous expectation of commercialization in the second half of this year. Pfizer is also lowering its 2023 revenue expectations for Comirnaty by approximately $2 billion due to lower-than-expected vaccination rates.Pfizer Inc. now foresees 2023 revenue in a range of $58 billion to $61 billion, down from its prior forecast for $67 billion to $70 billion. It now projects full-year adjusted earnings between $1.45 and $1.65 per share due to lower-than-anticipated revenue for COVID-19-related products and inventory write-offs.That is short of the full-year revenue of $63.61 billion and earnings of $2.77 per share that Wall Street was expecting, and far short of the company's previous projections of per-share earning between $3.25 and $3.45. JPMorgan said the company's update solves an ongoing U.S. Paxlovid inventory debate and it anticipates the company's bigger-than-expected cuts to its sales projections will help put a floor under per-share earnings expectations for next year.。    海峡网讯（记者 李牧晨 通讯员 何羚珊）8月21日，海杰航运“利雅得穆卡布”轮顺利靠泊福州港江阴港区，标志着2026年度中欧北极快航正式首靠福州港。本航次为该航线今年首次挂靠福建，福州江阴港区也是本次航次全省唯一挂靠港口，进一步畅通了我省对欧绿色、高效海上物流通道。         据了解，中欧北极快航依托北极东北航道通行，相较传统苏伊士运河航线，航程缩短超15天，运输时效显著提升，同时有效规避传统远洋航线复杂地缘风险，船舶航行碳排放减少约30%，具备时效快、安全性高、绿色低碳等突出优势。航线主要承载我省新能源、新材料等外贸重点货物出口，为福建“新三样”产品远销欧洲搭建了稳定高效的海上大动脉。    为保障本次首航船舶安全、高效完成靠泊装卸作业，福州海事局提前部署、精准施策，全面落实全过程安全监管与便民服务举措。该局提前开展通航环境风险研判，结合季节气象、航道条件、港口作业特点，梳理航行靠泊、货物装卸等关键环节风险点，主动对接码头、航运企业，督促落实安全生产主体责任，细化完善作业保障方案。         作业期间，福州海事局依托“现场巡航+电子巡查”双防管控模式，实时掌握船舶动态及港区作业秩序，严格核查船舶适航状态、船员履职情况及集装箱绑扎系固安全条件，全程紧盯现场作业安全，及时排查整治水域安全隐患。同时主动联动引航、拖轮、港口运营等相关单位，畅通信息共享渠道，优化船舶进出港、靠离泊保障流程，最大限度压缩船舶在港周转时间，持续提升港口通关作业效能。         近年来，福州港江阴港区持续加密国际集装箱航线网络，北极快航的常态化运行，进一步丰富了我省远洋航运布局。下一步，福州海事局将持续聚焦外贸航运保通保畅，不断优化海事监管服务举措，强化重点国际航线、重点外贸船舶全链条安全保障，全力保障跨境物流通道安全高效畅通，助力福州港打造区域性国际航运枢纽，服务地方外向型经济高质量发展。

Current article:http://alaf.longdachemakuanshan.pics/h1dk4t/iee.html

Published on:16:19:38